ClinicalTrials.gg
CompletedNCT07619443Updated Sep 25, 2026

A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

A Phase 1 interventional study of MK-7262 and Enlicitide in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Updated Sep 25, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a (BMI) ≥18 and ≤32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history or presence of medical or psychiatric condition or disease
  • Has a history of cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    MK-7262

    Participants will receive MK-7262 orally.

    Drug: MK-7262

  • Experimental
    Enlicitide

    Participants will receive enlicitide orally.

    Drug: Enlicitide

  • Experimental
    MK-7262 plus Enlicitide

    Participants will receive MK-7262 and enlicitide orally.

    Drug: MK-7262 · Drug: Enlicitide

Interventions

  • DrugMK-7262

    Oral administration

  • Oral administration

    Also known as: enlicitide decanoate, MK-0616

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262

    Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.

    Time frame: Predose and at designated time points post-dose (up to 8 days)

  2. AUC0-inf of Enlicitide

    Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  3. Maximum Plasma Concentration (Cmax) of MK-7262

    Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  4. Cmax of Enlicitide

    Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

Secondary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of MK-7262

    Blood samples will be collected at multiple time points to estimate the AUC0-24 of MK-7262.

    Time frame: Predose and at designated time points post-dose (up to 24 hours post-dose)

  2. Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-7262

    Blood samples will be collected at multiple time points to estimate the AUC0-last of MK-7262.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  3. Time to Maximum Plasma Concentration (Tmax) of MK-7262

    Blood samples will be collected at multiple time points to estimate the Tmax of MK-7262.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  4. Apparent Terminal Half-life (t1/2) of MK-7262

    Blood samples will be collected at multiple time points to estimate the t1/2 of MK-7262.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  5. Apparent Clearance (CL/F) of MK-7262

    Blood samples will be collected at multiple time points to estimate the CL/F of MK-7262.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  6. Apparent Volume of Distribution During Terminal Phase (Vz/F)of MK-7262

    Blood samples will be collected at multiple time points to estimate the Vz/F of MK-7262.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  7. AUC0-24 of Enlicitide

    Blood samples will be collected at multiple time points to estimate the AUC0-24 of enlicitide.

    Time frame: Predose and at designated time points post-dose (up to 24 hours post-dose)

  8. AUC0-last of Enlicitide

    Blood samples will be collected at multiple time points to estimate the AUC0-last of enlicitide.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  9. Tmax of Enlicitide

    Blood samples will be collected at multiple time points to estimate the Tmax of enlicitide.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  10. t1/2 of Enlicitide

    Blood samples will be collected at multiple time points to estimate the t1/2 of enlicitide.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  11. CL/F of Enlicitide

    Blood samples will be collected at multiple time points to estimate the CL/F of enlicitide.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  12. Vz/F of Enlicitide

    Blood samples will be collected at multiple time points to estimate the Vz/F of enlicitide.

    Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)

  13. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.

    Time frame: Up to approximately 8 weeks

  14. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 6 weeks

07

Study locations

1 site
  • Celerion ( Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Sep 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartActual
Jul 1, 2026
Primary completionActual
Sep 5, 2026
CompletionActual
Sep 22, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 25, 2026
Study completion
Sep 12, 2026→Sep 22, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Active, not recruiting→Completed
    Study completion Sep 12, 2026→Sep 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07619443
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jul 1, 2026
Primary completion
Sep 5, 2026
Completion
Sep 22, 2026
Last update
Sep 25, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide

Start the discussion